For the quarter ended March 2024, Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $172.33 million, up 284.2% over the same period last year. EPS came in at -$0.54, compared to -$1.56 in the ...
Source LinkFor the quarter ended March 2024, Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $172.33 million, up 284.2% over the same period last year. EPS came in at -$0.54, compared to -$1.56 in the ...
Source Link
Comments